Data Confirms Zytiga is Killing Dendreon's (DNDN) Provenge, But Don't Put the Nail in the Coffin Yet
Tweet Send to a Friend
Dendreon's (NASDAQ: DNDN) prostate cancer drug Provenge continues to underwhelm, but the game is still far from over said analysts ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
